Lemborexant (Dayvigo)

Lemborexant (Trade name: Dayvigo) is a dual orexin receptor antagonist (DORA) used in the treatment of insomnia.

Pharmacokinetics of Lemborexant

Lemborexant: Cytochrome P450 Metabolism

Substrate of (Metabolized by)
Induces
Inhibits
  • Blocks binding of orexin A and B to orexin receptors 1 and 2 respectively
  • Increases NREM and REM sleep
  • Reduces wakefulness
  • Insomnia disorder

Dosing for Lemborexant

Starting 5 mg PO qHS
Titration Increased by 5 mg PO qHS
Maximum 10 mg PO qHS
Taper
  • Lemborexant comes in
  • Headaches, sedation, vivid dreaming